Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The objective of The North American Menopause Society (NAMS) and The International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel was to create a point of care algorithm for treating genitourinary syndrome of menopause (GSM) in women with or at high risk for breast cancer. The consensus recommendations will assist healthcare providers in managing GSM with a goal of improving the care and quality of life for these women. The Expert Consensus Panel is comprised of a diverse group of 16 multidisciplinary experts well respected in their fields. The panelists individually conducted an evidence-based review of the literature in their respective areas of expertise. They then met to discuss the latest treatment options for genitourinary syndrome of menopause (GSM) in survivors of breast cancer and review management strategies for GSM in women with or at high risk for breast cancer, using a modified Delphi method. This iterative process involved presentations summarizing the current literature, debate, and discussion of divergent opinions concerning GSM assessment and management, leading to the development of consensus recommendations for the clinician. Genitourinary syndrome of menopause is more prevalent in survivors of breast cancer, is commonly undiagnosed and untreated, and may have early onset because of cancer treatments or risk-reducing strategies. The paucity of evidence regarding the safety of vaginal hormone therapies in women with or at high risk for breast cancer has resulted in avoidance of treatment, potentially adversely affecting quality of life and intimate relationships. Factors influencing decision-making regarding treatment for GSM include breast cancer recurrence risk, severity of symptoms, response to prior therapies, and personal preference. We review current evidence for various pharmacologic and nonpharmacologic therapeutic modalities in women with a history of or at high risk for breast cancer and highlight the substantial gaps in the evidence for safe and effective therapies and the need for future research. Treatment of GSM is individualized, with nonhormone treatments generally being first line in this population. The use of local hormone therapies may be an option for some women who fail nonpharmacologic and nonhormone treatments after a discussion of risks and benefits and review with a woman's oncologist. We provide consensus recommendations for an approach to the management of GSM in specific patient populations, including women at high risk for breast cancer, women with estrogen-receptor positive breast cancers, women with triple-negative breast cancers, and women with metastatic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shared decision making: A model for clinical practice
Elwyn, G., Frosch, D., Thomson, R., Joseph-Williams, N., Lloyd, A., Kinnersley, P., Cording, E., Tomson, D., Dodd, C., Rollnick, S., et al. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2077-6 · Cited by 4,405 · cited 1×
“The discussion about treatment options should include the mechanism of action, if known; potential adverse effects; current data regarding efficacy and safety; and the benefits and risks of each treatment option.(39) Clinicians should evaluate the woman’s perceived need for treatment versus fears regarding breast canc…”
BackgroundDomchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494
Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., Cannady, R. S., Pratt-Chapman, M. L., Edge, S. B., Jacobs, L. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.3809 · Cited by 1,071 · cited 1×
“estrogen-based treatments are controversial or discouraged for women with a history of or at high risk for breast cancer.(20)”
BackgroundExemestane for Breast-Cancer Prevention in Postmenopausal Women
Goss, P. E., Ingle, J. N., Alés-Martínez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J., McTiernan, A., Robbins, J., Johnson, K. C., Martin, L. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103507 · Cited by 970
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
Self-citationRecognition and management of nonrelaxing pelvic floor dysfunction
Faubion, S. S., Shuster, L. T., & Bharucha, A. E. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.09.004 · Cited by 220
Self-citationMelisko, M. E., Goldman, M. E., Hwang, J., De Luca, A., Fang, S., Esserman, L. J., Chien, A. J., Park, J. W., & Rugo, H. S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3904 · Cited by 155 · cited 1×
“Despite the fact that women in the third trial were taking AIs, 12% had persistently elevated estradiol levels as well.(91)”
BackgroundMartel, C., Labrie, F., Archer, D. F., Ke, Y., Gonthier, R., Simard, J.-N., Lavoie, L., Vaillancourt, M., Montesino, M., Balser, J., et al. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.016 · Cited by 72
Cited by
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
“Treatment with low-dose vaginal ET or DHEA may be considered if symptoms persist after an initial trial of nonhormone therapies and in consultation with an oncologist, with more concern for women on AIs.”
InfluentialSelf-citation
Metadata
- Authors
- Faubion, S. S., Larkin, L. C., Stuenkel, C. A., Bachmann, G. A., Chism, L. A., Kagan, R., Kaunitz, A. M., Krychman, M. L., Parish, S. J., Partridge, A. H., Pinkerton, J. V., Rowen, T. S., Shapiro, M., Simon, J. A., Goldfarb, S. B., & Kingsberg, S. A.
- Venue
- Menopause
- Published
- 2018-06
- Volume
- 25
- Issue
- 6
- Pages
- 596-608
- ISSN
- 1072-3714 (ISSN-L)
- 1530-0374
- OpenAlex
- W2804540714
- Cited by
- 243
- References
- 8
- FWCI
- 15.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. https://app.cochat.ai/papers/10.1097/gme.0000000000001121
- The paper
- Faubion, S. S., Larkin, L. C., Stuenkel, C. A., Bachmann, G. A., Chism, L. A., Kagan, R., Kaunitz, A. M., Krychman, M. L., Parish, S. J., Partridge, A. H., Pinkerton, J. V., Rowen, T. S., Shapiro, M., Simon, J. A., Goldfarb, S. B., & Kingsberg, S. A. (2018). Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause. https://doi.org/10.1097/gme.0000000000001121
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.